SCLX
Scilex Holding Co
Key Financials
Gross Profit
$125.8M
↓ 24.9%
Revenue
$30.3M
↓ 46.5%
Net Income
$-374053000
↓ 413.8%
Operating Income
$-346007000
↓ 314.9%
EPS (Diluted)
$-36.48
↓ 5880.3%
Total Assets
$365.0M
↑ 292.7%
Shareholders' Equity
$-207781000.00
↓ 7.9%
Total Liabilities
$576.7M
↑ 101.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 8/14/2026 | View on SEC |
| 8-K | 8/12/2026 | View on SEC |
| 8-K | 7/22/2026 | View on SEC |
| SCHEDULE 13D/A | 7/7/2026 | View on SEC |
| 4 | 7/7/2026 | View on SEC |
| 8-K | 7/6/2026 | View on SEC |
| S-8 | 6/30/2026 | View on SEC |
| 8-K | 6/29/2026 | View on SEC |
| SCHEDULE 13D/A | 6/26/2026 | View on SEC |
| 4 | 6/26/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | SCLX |
| Company Name | Scilex Holding Co |
| CIK | 1820190 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (650) 516-4310 |